ILMN vs. TEM: Illumina vs. Tempus AI Stock Comparison
How do Illumina (ILMN) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Illumina (ILMN) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
Illumina (ILMN) carries decades of public-market history since July 28, 2000, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the ILMN side.
| Profile Item | ILMN | TEM |
|---|---|---|
| Name | Illumina Inc. | Tempus AI Inc Class A Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 32.23 billion USD | 13.87 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 28, 2000 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Total Return (1Y) | 79.70% | 16.25% |
| Total Return (3Y, Annualized) | 28.16% | -- |
| Total Return (5Y, Annualized) | -10.65% | -- |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Volatility (1Y, Annualized) | 48.47% | 76.08% |
| Beta (5Y) | 1.46 | 3.34 |
| Max Drawdown (5Y) | -82.95% | -59.76% |
| Avg. Volume (3M) | 2.77M | 7.20M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Sharpe Ratio (1Y) | 1.56 | 0.16 |
| Sortino Ratio (1Y) | 2.25 | 0.26 |
Profitability
ROE (TTM)
Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.39%
- Max
- 109.18%
- ILMN
- 32.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.72%
- ILMN
- 19.72%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Illumina (ILMN) reports 20.02%, ranking against industry peers normally.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 83.12%
- ILMN
- 20.02%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ILMN | TEM |
|---|---|---|
| ROE (TTM) | 32.39% | -37.55% |
| ROA (TTM) | 8.32% | -7.36% |
| Net Margin (TTM) | 19.72% | -12.54% |
| Operating Margin (TTM) | 20.02% | -13.82% |
| Gross Margin (TTM) | 67.68% | 64.46% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Illumina (ILMN) at -0.66% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither Illumina (ILMN) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Revenue Growth (YoY) | -0.66% | 83.41% |
| Revenue Growth (3Y CAGR) | -1.78% | 58.29% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Illumina (ILMN) at 2.63 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ILMN
- 2.63
- Q1
- 2.47
- Min
- 0.10
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Illumina (ILMN) at 0.74 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.74
- Max
- 1.42
- ILMN
- 0.74
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Current Ratio (MRQ) | 2.63 | 2.61 |
| Debt / Equity (MRQ) | 0.74 | 2.86 |
| Net Debt / EBITDA | 0.85 | -- |
Dividends
Dividend Yield (TTM)
Neither Illumina (ILMN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Illumina (ILMN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ILMN | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.68
- Max
- 85.34
- Q3
- 43.46
- ILMN
- 36.68
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
P/S Ratio (TTM)
On P/S ratio, both Illumina (ILMN) at 7.10 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.10
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ILMN
- 7.10
- Q1
- 3.01
- Min
- 0.01
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.30
- Max
- 13.53
- ILMN
- 10.30
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ILMN | TEM |
|---|---|---|
| P/E Ratio (TTM) | 36.68 | -- |
| P/S Ratio (TTM) | 7.10 | 9.19 |
| P/B Ratio (MRQ) | 10.30 | 27.66 |
| Free Cash Flow Yield (TTM) | 2.67% | 0.30% |